Get started
Author

Annette L. Ervin-Haynes

Observed names: A Ervin-Haynes, A. Ervin-Haynes, Annette Ervin-Hayes, Annette Ervin-Haynes, Annette Ervin‐Haynes
Institution: Servier (France)
Observed institutions: University of Nebraska at Omaha, Fox Chase Cancer Center, Roswell Park Comprehensive Cancer Center, Nebraska Medical Center, Sunnybrook Health Science Centre, Mayo Clinic, Montefiore Medical Center, University of Miami, Inserm, New York Medical College, Genmab (United States), Centre Hospitalier Universitaire de Bordeaux, University Medical Center Utrecht, Hôpital Saint-Antoine, Centre Hospitalier Universitaire de Poitiers, Centre Hospitalier Universitaire de Caen Normandie, Mayo Clinic in Arizona, University of Colorado Cancer Center, Servier (France), Institut Paoli-Calmettes, Sylvester Comprehensive Cancer Center, Celgene (United States), UC Davis Comprehensive Cancer Center, Saskatoon Cancer Centre, Odette Cancer Centre, University of Nebraska Medical Center, University of California, Davis
OpenAlex ID: A5046116136
Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Myeloma
2014 · Lotfi Benboubker, Meletios A. Dimopoulos, et al. · New England Journal of Medicine · 794
PDF
Lenalidomide Monotherapy in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma
2008 · Peter H. Wiernik, Izidore S. Lossos, et al. · Journal of Clinical Oncology · 371
PDF
Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma
2017 · Thierry Facon, Meletios A. Dimopoulos, et al. · Blood · 271
PDF
Lenalidomide Oral Monotherapy Produces Durable Responses in Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma
2009 · Thomas E. Witzig, Peter H. Wiernik, et al. · Journal of Clinical Oncology · 260
Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma
2009 · Thomas M. Habermann, Izidore S. Lossos, et al. · British Journal of Haematology · 244
PDF
Updated Outcomes and Impact of Age With Lenalidomide and Low-Dose Dexamethasone or Melphalan, Prednisone, and Thalidomide in the Randomized, Phase III FIRST Trial
2016 · Cyrille Hulin, Andrew Belch, et al. · Journal of Clinical Oncology · 83
Initial Phase 3 Results Of The First (Frontline Investigation Of Lenalidomide + Dexamethasone Versus Standard Thalidomide) Trial (MM-020/IFM 07 01) In Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts) Ineligible For Stem Cell Transplantation (SCT)
2013 · Thierry Facon, Meletios A. Dimopoulos, et al. · Blood · 59
Impact of renal impairment on outcomes with lenalidomide and dexamethasone treatment in the FIRST trial, a randomized, open-label phase 3 trial in transplant-ineligible patients with multiple myeloma
2015 · M. A. Dimopoulos, M. C. Cheung, et al. · Haematologica · 40
Confirmation of the Efficacy and Safety of Lenalidomide Oral Monotherapy in Patients with Relapsed or Refractory Mantle-Cell Lymphoma: Results of An International Study (NHL-003)
2008 · Pier Luigi Zinzani, Thomas E. Witzig, et al. · Blood · 35
Preliminary Results from a Phase II Study of Lenalidomide Monotherapy in Relapsed/Refractory Aggressive Non-Hodgkin’s Lymphoma.
2006 · Peter H. Wiernik, Izidore Lossos, et al. · Blood · 32
A phase I dose-escalation study of weekly IMC-1121B, a fully human anti-vascular endothelial growth factor receptor 2 (VEGFR2) IgG1 monoclonal antibody (Mab), in patients (pts) with advanced cancer
2006 · D. R. Camidge, S. G. Eckhardt, et al. · Journal of Clinical Oncology · 30
Cost-effectiveness of lenalidomide plus dexamethasone vs bortezomib plus melphalan and prednisone in transplant-ineligible US patients with newly-diagnosed multiple myeloma
2015 · S. Z. Usmani, J. D. Cavenagh, et al. · Journal of Medical Economics · 28
PDF
Early Results from a Phase II Study of Lenalidomide Monotherapy in Relapsed/Refractory Indolent Non-Hodgkin’s Lymphoma.
2006 · Thomas E. Witzig, Julie M. Vose, et al. · Blood · 27
First-in-human, dose-escalation, phase (ph) I trial to evaluate safety of anti-Axl antibody-drug conjugate (ADC) enapotamab vedotin (EnaV) in solid tumors.
2019 · Malaka Ameratunga, R Donald Harvey, et al. · Journal of Clinical Oncology · 21
OA02.05 First-In-Human Phase 1/2 Trial of Anti-AXL Antibody–Drug Conjugate (ADC) Enapotamab Vedotin (EnaV) in Advanced NSCLC
2019 · S. Ramalingam, J. Lopez, et al. · Journal of Thoracic Oncology · 20
PDF
Benefit of continuous treatment for responders with newly diagnosed multiple myeloma in the randomized FIRST trial
2017 · N J Bahlis, A Corso, et al. · Leukemia · 20
PDF
Impact of Cytogenetics on Outcomes of Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma Treated with Continuous Lenalidomide Plus Low-Dose Dexamethasone in the First (MM-020) Trial
2015 · Herve Avet-Loiseau, Cyrille Hulin, et al. · Blood · 18
Continuous treatment with lenalidomide and low‐dose dexamethasone in transplant‐ineligible patients with newly diagnosed multiple myeloma in Asia: subanalysis of the FIRST trial
2017 · Jin Lu, Jae H. Lee, et al. · British Journal of Haematology · 17
PDF
Planned Interim Analysis of a Phase 2 Study of Loncastuximab Tesirine Plus Ibrutinib in Patients with Advanced Diffuse Large B-Cell Lymphoma (LOTIS-3)
2021 · Carmelo Carlo-Stella, Pier Luigi Luigi Zinzani, et al. · Blood · 16
A Frailty Scale Predicts Outcomes of Patients with Newly Diagnosed Multiple Myeloma Who Are Ineligible for Transplant Treated with Continuous Lenalidomide Plus Low-Dose Dexamethasone on the First Trial
2015 · Thierry Facon, Cyrille Hulin, et al. · Blood · 16
Preliminary results from a phase II study of lenalidomide oral monotherapy in relapsed/refractory aggressive non-Hodgkin lymphoma
2007 · P. H. Wiernik, I. S. Lossos, et al. · Journal of Clinical Oncology · 15
Lenalidomide and low‐dose dexamethasone in Japanese patients with newly diagnosed multiple myeloma: A phase II study
2016 · Kenshi Suzuki, Atsushi Shinagawa, et al. · Cancer Science · 14
PDF
Phase II Multicenter Study of the Safety and Efficacy of Single-Agent Lenalidomide in Subjects with Relapsed/Refractory Mantle Cell Lymphoma: Long-Term Follow-up Analysis of the NHL-003 Study.
2012 · Pier Luigi Zinzani, Julie M Vose, et al. · Blood · 14
Preliminary results from a phase II study of lenalidomide oral monotherapy in relapsed/refractory indolent non-Hodgkin lymphoma
2007 · T. E. Witzig, J. Vose, et al. · Journal of Clinical Oncology · 14
Long-term health-related quality of life in transplant-ineligible patients with newly diagnosed multiple myeloma receiving lenalidomide and dexamethasone
2017 · Dan T. Vogl, Michel Delforge, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 13
Works count: 65
Citation count: 2,591
H-index: 17
I10-index: 27
Year
Topic
Type